Comparative Pharmacology
Head-to-head clinical analysis: NEULASTA versus NEUPOGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEULASTA versus NEUPOGEN.
NEULASTA vs NEUPOGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pegfilgrastim is a recombinant methionyl human granulocyte colony-stimulating factor (G-CSF) conjugated to polyethylene glycol. It binds to G-CSF receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation, and release of neutrophils from the bone marrow.
Filgrastim is a human granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. It acts by binding to G-CSF receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation, and maturation of neutrophils.
6 mg subcutaneously once per chemotherapy cycle, administered at least 24 hours after cytotoxic chemotherapy and at least 14 days before next cycle.
5 mcg/kg subcutaneously or intravenously once daily for up to 14 days, or until absolute neutrophil count reaches 10,000/mm³ after nadir. For mobilization of peripheral blood progenitor cells: 10 mcg/kg subcutaneously once daily for 6-7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 15-23 hours (mean ~18 hours) in healthy subjects, allowing for once-per-cycle dosing for chemotherapy-induced neutropenia.
3.5 hours (range 2.5–4.5 hours) in healthy subjects; terminal elimination half-life is prolonged in patients receiving chemotherapy due to decreased clearance, approximately 5.5 hours.
Primarily renal clearance (through glomerular filtration and proteolytic degradation). Approximately 80% of the dose is eliminated renally as degraded peptides.
Primarily renal; greater than 90% of filgrastim is eliminated via renal excretion as intact protein and degraded metabolites. Biliary/fecal excretion is minimal (<1%).
Category C
Category C
Colony-Stimulating Factor
Colony-Stimulating Factor